Tarkenna hakuasi

Proteiinitekniikka ja Biokemia profiilikuva

Proteiinitekniikka ja Biokemia

Tutkimusryhmä
01.01.2023 -
Farmasian laitos, Terveystieteiden tiedekunta

Johtajat

Esittelykuva ryhmästä Proteiinitekniikka ja Biokemia

PEBBLE GROUP

The demand for biological medicines in healthcare is steadily increasing. The PEBBLE laboratory addresses this need by providing high-quality protein production capabilities that support multiple UEF research communities. Going beyond simple bacterially produced proteins, we enable local production, formulation, and quality assurance of diverse, complex proteins required for biologics development and translational medicine. By bridging fundamental biochemistry with clinical applications, the PEBBLE lab offers specialised facilities for the production, characterisation, and formulation of protein-based therapeutics and diagnostic reagents that require expression in living cell systems.

Recombinant Protein Production

We provide expertise in recombinant protein production, purification, and their biophysical and functional characterisation.
Our research focuses on bridging academic and clinical studies to advance drug and diagnostic development. Key areas of activity include:
·  Recombinant Protein Production: Utilising bacterial, insect (ExpiSF9), and mammalian (HEK293F) cell culture systems to produce functional recombinant proteins and their further purification.
·   Protein Characterisation: Advanced structural and functional analysis, including binding interaction studies and thermal stability analysis.
·   Biotherapeutic Development: Supporting the development of Advanced Therapy Medicinal Products (ATMPs) and biotherapeutics.
·   Methodology Development: Optimising protocols for PCR, ligation-independent cloning, and specialised affinity purification (Ni-NTA and Strep-Tactin® XT), Gel-filtration/ Size-exclusion chromatography, Hydrophobic Interaction chromatography, Ion-Exchange chromatography.

Vaccine delivery

Our group develops protein-based and microbial platforms for mucosal vaccine delivery by integrating protein engineering, immunology, and microbiology. We focus on targeted antigen delivery and protection at mucosal surfaces using M-cell–targeted nanobody platforms for intranasal vaccines and acid-resistant, non-pathogenic E. coli vehicles for oral vaccination, with the goal of inducing protective immunity at sites of pathogen entry.

Furthermore, we are looking for motivated master’s students (including Erasmus trainees) and PhD candidates to join our research group. By joining the PEBBLE group, you will gain hands-on experience in molecular biology, protein engineering, FPLC purification, and biophysical characterisation of proteins within a multidisciplinary environment.

Contact us to explore collaborative projects, service pricing, or thesis opportunities

[email protected]

Ajankohtaista

Active Projects and Collaborations

Since its inception in September 2023, PEBBLE has completed 15 protein purification collaborative projects. Protein Production is mainly carried out in mammalian, bacterial, and insect cell systems. Our current portfolio includes:

    • Neurological Research: Production of Tau and alpha-synuclein proteins
    • Cardiovascular Research: Production and development of VEGF-B and its variants for the CVD Research
    • Cancer Research: Production and purification of NRF transcription factor subdomains.
    • Key Proteins Produced for drug design and structural biology: Carbonic Anhydrase II, N-myristoylated viral protein, Argonaute-2 (wild type and mutant), Neuropilin B domain, and various protein kinases (ADCK3, PIP4K2C, NLK-1).
    • Acid-tolerant E.coli developed by the PEBBLE Lab

Infrastructure & Equipments


The infrastructure operates on an open-access principle for both academic groups and industry partners.

  • Purification: Äkta Pure and Äkta Prime Plus FPLC systems.
  • Interactions: Differential Scanning Fluorimetry and Nanotemper Monolith Microscale Thermophoresis for mapping protein-ligand and protein-protein interactions.
  • Cell Culture: High-speed centrifuges (Avanti J-26) and specialised incubator shakers for bacterial, insect, and mammalian scale-up.
  • Resources: A comprehensive repository of plasmids and a full proteomic dataset of the BL21-DE3 E. coli strain.

Tiedostot

1 kappaletta

Avainsanat